Percutaneous pulmonary valve implantation alters electrophysiologic substrate by Nguyen, Hoang H et al.




Percutaneous pulmonary valve implantation alters
electrophysiologic substrate
Hoang H. Nguyen
Washington University School of Medicine in St. Louis
Shabana Shahanavaz
Washington University School of Medicine in St. Louis
George F. Van Hare
Washington University School of Medicine in St. Louis
David T. Balzer
Washington University School of Medicine in St. Louis
Ramzi Nicolas
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Nguyen, Hoang H.; Shahanavaz, Shabana; Van Hare, George F.; Balzer, David T.; Nicolas, Ramzi; and Avari Silva, Jennifer N.,




Hoang H. Nguyen, Shabana Shahanavaz, George F. Van Hare, David T. Balzer, Ramzi Nicolas, and Jennifer N.
Avari Silva
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5451
Percutaneous Pulmonary Valve Implantation Alters Electrophysiologic
Substrate
Hoang H. Nguyen, MD; Shabana Shahanavaz, MBBS; George F. Van Hare, MD, FHRS; David T. Balzer, MD; Ramzi Nicolas, MD;
Jennifer N. Avari Silva, MD, FHRS
Background-—Percutaneous pulmonary valve implantation (PPVI) is ﬁrst-line therapy for some congenital heart disease patients
with right ventricular outﬂow tract dysfunction. The hemodynamics improvements after PPVI are well documented, but little is
known about its effects on the electrophysiologic substrate. The objective of this study is to assess the short- and medium-term
electrophysiologic substrate changes and elucidate postprocedure arrhythmias.
Methods and Results-—A retrospective chart review of patients undergoing PPVI from May 2010 to April 2015 was performed.
A total of 106 patients underwent PPVI; most commonly these patients had tetralogy of Fallot (n=59, 55%) and pulmonary
insufﬁciency (n=60, 57%). The median follow-up time was 28 months (7-63 months). Pre-PPVI, 25 patients (24%) had documented
arrhythmias: nonsustained ventricular tachycardia (NSVT) (n=9, 8%), frequent premature ventricular contractions (PVCs) (n=6, 6%),
and atrial ﬁbrillation/ﬂutter (AF/AFL) (n=10, 9%). Post-PPVI, arrhythmias resolved in 4 patients who had NSVT (44%) and 5 patients
who had PVCs (83%). New arrhythmias were seen in 16 patients (15%): 7 NSVT, 8 PVCs, and 1 AF/AFL. There was resolution at
medium-term follow-up in 6 (86%) patients with new-onset NSVT and 7 (88%) patients with new-onset PVCs. There was no
difference in QRS duration pre-PPVI, post-PPVI, and at medium-term follow-up (P=0.6). The median corrected QT lengthened
immediately post-PPVI but shortened signiﬁcantly at midterm follow-up (P<0.01).
Conclusions-—PPVI reduced the prevalence of NSVT. The majority of postimplant arrhythmias resolve by 6 months of follow-up.
( J Am Heart Assoc. 2016;5:e004325 doi: 10.1161/JAHA.116.004325)
Key Words: arrhythmia (heart rhythm disorders) • arrhythmia burden • electrocardiography • electrophysiology • percutaneous
pulmonary valve placement • pulmonary valve
C ongenital heart disease patients with right ventricularoutﬂow tract (RVOT) dysfunction have an increased
prevalence of arrhythmias associated with increasing age,
prior cardiac surgeries, QRS duration (QRSd), and degree of
pulmonary regurgitation and stenosis.1,2 Percutaneous pul-
monary valve implantation (PPVI) using the Melody (Med-
tronic Inc, Minneapolis, MN) valve has become a safe and
feasible alternative treatment option to surgical pulmonary
valve replacement.3,4 Because PPVI does not include
incisions in the RV myocardium, it serves as a better model
to evaluate any hemodynamics and electrophysiologic sub-
strate changes with pressure and volume load reduction.
Improvements in hemodynamics parameters after the pro-
cedure have been demonstrated in several reports.5-9
However, few reports have investigated changes in ECG
parameters along with the prevalence and type of arrhyth-
mias post-PPVI.10,11
The goals of this study are to (1) describe the short-term
and medium-term changes to the electrophysiologic sub-
strate (as identiﬁed by surface ECG) in patients following
PPVI and (2) determine the type and prevalence of
arrhythmias (including premature ventricular complexes
[PVCs], nonsustained ventricular tachycardia [NSVT], and
atrial ﬁbrillation/atrial ﬂutter [AF/AFL]) in post-PPVI
patients.
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On obtaining full approval from the institutional review board
at Washington University in St. Louis School of Medicine
(waiver of consent), we undertook a retrospective chart
review of patients who underwent PPVI in the pulmonary
valve position at St. Louis Children’s Hospital from May 1,
2010 to April 30, 2015. The previously described inclusion
criteria for PPVI include (1) RV systolic pressure greater than
two thirds of systemic with symptoms or (2) RV systolic
pressure greater than three fourths of systemic in absence
of symptoms or (3) moderate/severe pulmonary regurgita-
tion with either symptoms or severe RV dysfunction or
severe RV dilatation or impaired exercise capacity.5,12
Patients were excluded if the Melody valve (Medtronic Inc,
Minneapolis, MN) was implanted in the branch pulmonary
arteries or tricuspid position (n=4). Patients were classiﬁed
as having predominantly pulmonary insufﬁciency (PI) if they
had at least moderate pulmonary regurgitation on echocar-
diography; they were classiﬁed as having predominantly
pulmonary stenosis (PS) if they had a mean RVOT gradient
≥35 mm Hg on echocardiogram. When the gradient could
not be determined due to poor acoustic windows, a systolic
gradient ≥35 mm Hg during the catheterization was used as
the inclusion criterion for the pulmonary stenosis group.
Patients with both stenosis and insufﬁciency were included
in the mixed-lesion group (PS/PI). Charts were then
reviewed for demographic information, clinical and procedu-
ral characteristics, and electrophysiologic data (including
ECGs, 24-hour Holter monitors, electrophysiology studies
[EPS], cardiac rhythm device reports and transmissions, and
telemetry). ECGs preprocedure, 24 hours postprocedure, and
at last follow-up visit were analyzed. Corrected QT (QTc)
intervals were calculated using the Bazett formula. Postpro-
cedural overnight telemetry alarms and Holter monitors pre-
and postprocedure were reviewed for ECG changes and
arrhythmia. Right bundle branch block (RBBB) was deﬁned
as a QRS duration of ≥120 milliseconds. NSVT was deﬁned
as 3 or more consecutive PVCs with rates faster than
180 beats per minute.
Statistical Analysis
Summary data are presented as frequency with percentage.
Continuous data are not normally distributed and therefore
are presented as median with interquartile range. The
Wilcoxon signed-ranks test and the Friedman test were used
to compare continuous data. The Fisher exact test was used
to compare nominal variables between pre- and post-PPVI
groups. Statistical signiﬁcance was deﬁned as P<0.05. All
statistical analyses were performed using SPSS statistical
software (version 22.0; IBM Corp, Armonk, NY).
Results
Patient Clinical Data
A total of 106 patients, 40 female (38%) and 66 male (62%),
were included in this study. Median age at the time of the





Age, y 20.7 (16.7)
Weight, kg 65.5 (32)
Cardiac diagnosis
Tetralogy of Fallot 59 (55%)
Pulmonary stenosis 14 (13%)
Aortic stenosis 14 (13%)
Truncus arteriosus 7 (7%)
Double-outlet right ventricle 6 (6%)
Other 6 (6%)
RVOT dysfunction type
Pulmonary insufficiency 60 (57%)
Pulmonary stenosis 26 (25%)
Mixed pulmonary insufficiency/stenosis 20 (18%)
Antiarrhythmic medication*
Class II 22 (21%)
Class III 3 (3%)
Class IV 5 (5%)
Cardiac medication*
Diuretics 22 (21%)
ACE inhibitor 19 (18%)
ARB 2 (2%)
Digoxin 19 (18%)
PHTN medications 2 (2%)
Previous electrophysiology study 10 (9%)
With ablation 3 (3%)
Without ablation 7 (7%)
Cardiac rhythm device 16 (15%)
Single-chamber pacemaker 2 (2%)
Dual-chamber pacemaker 5 (5%)
Biventricular pacemaker 1 (1%)
Intracardiac defibrillator 8 (7%)
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker;
PHTN, pulmonary hypertension; RVOT, right ventricular outﬂow tract.
*Numbers indicate instances medications were used and not the numbers of patients.
All medications are pre-PPVI.
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procedure was 20.7 years (IQR 14.5-31.2). The most common
congenital anatomic diagnosis was tetralogy of Fallot (ToF)
(55%), and the most common type of RVOT dysfunction was
pulmonary insufﬁciency (57%). Prior to the procedure, 10 (9%)
patients had undergone EPS, 3 of which included an ablation
attempt. All the EPS with ablation attempts occurred more
than 3 years prior to the PPVI. Implanted cardiac rhythm
devices were present in 16 (15%) patients (Table 1). Two
patients were deceased during follow-up. One patient died
from complications of epithelioid hemangioendothelioma. This
patient did not have documented arrhythmia or ST/T changes
pre- or post-PPVI. The second patient developed endocarditis
of the Melody valve 2 years postimplant that was being
treated with intravenous antibiotics. He had documented
PVCs pre- and post-PPVI. He had an out-of-hospital sudden
cardiac arrest.
Hemodynamics Data
A total of 46 patients had pulmonary stenosis (26 PS patients
and 20 PS/PI patients) with a median pre-PPVI RVOT gradient
of 42 mm Hg (IQR 37-50). Median RVOT gradient signiﬁcantly
lowered immediately post-PPVI to 11 mm Hg (IQR 8-15)
(P<0.001). Forty patients had echocardiographic data avail-
able at medium-term follow-up. In these patients the median
RVOT gradient remained stable at 11.5 mm Hg (IQR 7-19)
(Figure 1). Of the PI patients, only 1 patient had more than a
mild degree of pulmonary regurgitation at last follow-up. This
patient developed endocarditis of the Melody valve, leading to
free pulmonary regurgitation. He had an out-of-hospital
sudden cardiac arrest. No patients had reintervention on
the Melody valve.
Electrocardiographic Changes
Sixteen patients with cardiac rhythm devices were excluded
from this portion of the data analysis. There was no difference
between the pre- and post-PPVI median QRSd (141 [IQR 110-
157] milliseconds vs (140 [IQR 101-157] milliseconds,
Figure 1. Comparison of RVOT pressure gradients of predomi-
nantly PS patients. There was a signiﬁcant reduction in RVOT
pressure gradients immediately post-PPVI. These pressure gradi-
ents remained stable at follow-up. RVOT indicates right ventricular
outﬂow tract.
Figure 2. Comparison of ECG parameters. A, QRS duration (QRSd) is compared pre-PPVI, post-PPVI, and at follow-up. There was no signiﬁcant
difference in QRSd among time points (P=0.6). B, Corrected QT interval (QTc, calculated using the Bazett formula) compared pre-PPVI, post-
PPVI, and at follow-up. The QTc was prolonged immediately post-PPVI, but it signiﬁcantly shortened at follow-up (P<0.01). PPVI indicates
percutaneous pulmonary valve implantation; QRSd, QRS duration; QTc, corrected QT interval.
DOI: 10.1161/JAHA.116.004325 Journal of the American Heart Association 3























P=0.07). The baseline median QTc was 460 [IQR 436-486]
milliseconds, which lengthened immediately post-PPVI
(475 [IQR 450-504] milliseconds, P<0.01). Medium-term
follow-up ECGs were available in 58 patients with median
follow-up time of 28 months (7-63 months). At follow-up time
of at least 7 months post-PPVI, there was no statistical
signiﬁcance in the median QRSd (pre-PPVI=137 [IQR 107-
155] milliseconds, post-PPVI=137 [IQR 98–154] milliseconds,
follow-up=137 [IQR 103-157] milliseconds, P=0.8). The
median QTc shortened signiﬁcantly to 442 [IQR 420-465]
milliseconds at follow-up when compared to pre-PPVI (463
[IQR 435-483] milliseconds, P<0.001) and immediately post-
PPVI (476 [IQR 452-507] milliseconds, P<0.001) (Figure 2).
Subgroup analysis by cardiac diagnosis or type of RVOT
dysfunction yielded similar results (Table 2). Interestingly, the
median pre-PPVI QTc of patients with pulmonary stenosis was
shorter than that of patients with pulmonary regurgitation
(P=0.07), whereas the median post-PPVI QTc of patients with
pulmonary stenosis was longer than that of patients with
pulmonary regurgitation (P<0.001).
At baseline, 23/90 (26%) patients had ST/T changes: 5
patients (6%) had ST depression, 7 patients (8%) had T-wave
inversion, and 11 patients (12%) had nonspeciﬁc ST/T
changes. Immediately post-PPVI, there were new-onset ST
depression (n=1), T-wave inversion (n=5), and nonspeciﬁc ST/
T changes (n=5). However, at follow-up all these new ST/T
changes had resolved. Overall, ST/T changes resolved in
100% of cases with ST depression, 88% of cases with T-wave
inversion, and 80% of cases with ST/T changes (Figures 3
through 5; Figure S1).
Arrhythmia Burden
Pre-PPVI, 27/106 patients (25%) had documented arrhyth-
mias. Nine patients (8%) had NSVT, 6 patients (6%) had
frequent PVCs, 10 patients (10%) had atrial AF/AFL, and 2
patients (2%) had supraventricular tachycardia. Only 2/8
Table 2. ECG Parameter Changes by Cardiac Diagnosis and Type of RVOT Dysfunction
ECG Parameters Pre-PPVI Post-PPVI Follow-Up P Value
Tetralogy of Fallot
QRSd, ms 144 [IQR 120-161] 140 [IQR 107-159] 139 [IQR 108-160] 0.9
QTc, ms 469 [IQR 439-487] 480 [IQR 454-518] 447 [IQR 417-464] <0.001
Pulmonary insufficiency
QRSd, ms 132 [IQR 95-156] 133 [IQR 96-153] 137 [IQR 100-156] 0.9
QTc, ms 469 [IQR 436-484] 470 [IQR 445-496] 442 [IQR 420-465] <0.001
Pulmonary stenosis
QRSd, ms 144 [IQR 119-155] 140 [IQR 101-154] 140 [IQR 107-162] 0.7
QTc, ms 437 [IQR 433-460] 475 [IQR 454-513] 439 [IQR 405-467] 0.006
Mixed PS/PI
QRSd, ms 144 [IQR 99-149] 146 [IQR 92-158] 134 [IQR 108-162] 0.7
QTc, ms 474 [IQR 460-504] 503 [IQR 484-519] 445 [IQR 421-471] 0.004
There was no statistical signiﬁcance in the QRSd across time points regardless of cardiac diagnosis or type of RVOT dysfunction. The QTc prolonged signiﬁcantly immediately post-PPVI but
shortened signiﬁcantly at follow-up in all subgroups. ECG indicates electrocardiogram; PPVI, percutaneous pulmonary valve implantation; PS/PI pulmonary stenosis/pulmonary
insufﬁciency; RVOT right ventricular outﬂow tract.
Figure 3. ST depression on ECG. Five patients had ST depression
pre-PPVI. Immediately postprocedure, there was resolution of ST
depression in 2 (40%) patients, while 3 (60%) patients continued to
have unchanged ST depression. Patients who had resolved ST
depression post-PPVI did not have further ECGs at follow-up.
Additionally, 1 patient had a new-onset ST depression on ECG. Both
the new-onset and persistent ST depression postprocedure
resolved at follow-up. PPVI indicates percutaneous pulmonary
valve implantation.
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(25%) patients with pre-PPVI VT, and no patient with pre-PPVI
AF/AFL was in the PS group. New-onset arrhythmias
immediately post-PPVI include 7 patients with NSVT, 8
patients with PVCs, and 1 patient with AF/AFL. These
arrhythmias were recorded on overnight telemetry. Once
again, there were very few PS-only patients (3/16, 19%) in
this cohort. At follow-up, these new-onset arrhythmias
resolved in 86% of NSVT cases and 88% of PVCs cases.
Two out of 8 patients with new-onset PVCs were started on
b-blockers, which were discontinued at their 6-month follow-
up. Two out of 7 patients with new-onset NSVT were started
on amiodarone. One of these patients was taken off the
amiodarone at 6 months of follow-up. The second patient
continued to be maintained on amiodarone without docu-
mented recurrence of NSVT. One patient was started on a
b-blocker and continued to be on this medication because he
had persistent documented PVCs. Overall, 12/16 (75%)
patients no longer had documented NSVT, and 12/14 (86%)
patients no longer had PVCs. One patient with PVCs prior to
the procedure continued to have PVCs postprocedure. This
patient also developed endocarditis of the Melody valve. He
had an out-of-hospital sudden cardiac arrest. Finally, AF/AFL
resolved in 6/11 (55%) cases (Figures 6 through 8; Figures S2
and S3). Arrhythmia burden was determined by Holter
monitoring, internal rhythm devices reports, and telemetry
during subsequent hospitalizations.
Imaging Correlation
Forty patients had cardiac MRI pre-PPVI, but only 4 had post-
PPVI studies for comparison (3 PS, 1 PI). Notably, the patient
with PI had markedly improved RVEDV post-PPVI. This patient
had nonspeciﬁc ST changes both pre- and post-PPVI, but
these changes resolved at follow-up. One patient with PS had
aneurysmal dilatation of the RVOT on follow-up MRI. This
patient had new-onset T-wave inversion at follow-up. The
remaining 2 patients did not have ECG changes or appreciable
structural changes on follow-up MRI.
Of the 39 patients with ECG changes (baseline + new
onset post-PPVI + new onset at follow-up), 27 patients had
ECG for analysis (Figures 5 through 7). Speciﬁcally, there
were 19 resolved ST/T changes, 3 persistent ST/T changes,
and 5 new-onset ST/T changes. All 27 patients had follow-up
ECGs. Although there was improvement in RV size by
echocardiogram in 15/27 (56%) patients, there was no
change noted in 12/27 (44%) patients. Among patients with
Figure 4. T-wave pattern on ECG. Seven patients had T-wave inversion pre-PPVI. Immediately
postprocedure, there was resolution of T-wave inversion in 4 (57%) patients, while 3 (43%) patients
continued to have unchanged T-wave inversion. Patients who had resolved T-wave inversion post-PPVI did
not have further ECGs at follow-up. Additionally, 5 patients had a new ﬁnding of T-wave inversion on ECG.
All new-onset T-wave inversions and 2 of 3 persistent T-wave inversions postprocedure resolved at follow-
up. One patient with persistent postprocedure T-wave inversion continued to have T-wave inversion at
follow-up. Finally, 4 patients had new T-wave inversions at follow-up. PPVI indicates percutaneous
pulmonary valve implantation.
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new-onset/persistent ECG changes at follow-up (n=8), there
were equal numbers of patients who had improved RV size
versus no appreciable change by follow-up echo. In the 19
patients who had resolved ECG changes at follow-up, 10
patients had improved RV size, whereas 9 patients did show
changes on follow-up echo. There appeared to be no
correlation between RV size and ECG changes.
Discussion
To our knowledge, this study is the ﬁrst to evaluate changes in
the electrophysiologic substrate and arrhythmia burden of
patients undergoing PPVI. Novel ﬁndings of this study include
the observations of acute newly developing ST/T changes and
arrhythmias such as frequent isolated PVCs and NSVT
immediately post-PPVI. Moreover, the study was able to
document improvement in the electrophysiologic substrate
changes and arrhythmia burden at medium-term follow-up.
Two previous studies have examined the effects of PPVI on
surface ECG parameters. Plymen et al10 studied conduction
(QRSd) and repolarization (QTc, QT, and JT dispersion)
parameters, and Piotrowicz et al11 studied parameters of RV
hypertrophy. Similar to previous reports, our study did not ﬁnd
a signiﬁcant change in QRSd post-PPVI in the overall cohort.
However, Plymen et al10 found signiﬁcant shortening of QRSd
in patients with pulmonary regurgitation.
QRSd has served as a marker to assess the risk of
arrhythmic death in congenital heart disease patients (partic-
ularly ToF) with RVOT dysfunction.2,13 Patients with PI who do
not undergo pulmonary valve replacement or PPVI have an
increase in QRSd of 2 to 4 milliseconds per year that is
associated with increasing right ventricular end-diastolic
volume (RVEDV).1,14,15 Because RVEDV decreases postsurgi-
cal pulmonary valve replacement, the procedure has been
postulated to improve the arrhythmia burden in patients with
chronic PI.16 Given the fact that PPVI serves as a better model
to study the effects of improvements in hemodynamics on
QRSd, Plymen et al’s10 particular ﬁndings could represent the
true proportional relationship between improvement in RVEDV
and decreasing QRSd. Unlike Plymen et al,10 this study did
Figure 5. Nonspeciﬁc ST/T changes on ECG. Eleven patients had ST/T changes pre-PPVI. Immediately
postprocedure, there was resolution of ST/T changes in 3 (27%) patients, while 8 (73%) patients continued
to have unchanged ST/T changes. Patients who had resolved ST/T changes post-PPVI did not have further
ECGs at follow-up. Additionally, 5 patients had a new ﬁnding of ST/T changes on ECG. All new-onset ST/T
changes and 3 of 8 (38%) persistent ST/T changes postprocedure resolved at follow-up. Two patients with
persistent postprocedure ST/T changes continued to have ST/T changes at follow-up. Finally, 1 patient had
new ST/T changes at follow-up. Of note, 3 patients were lost to follow-up. PPVI indicates percutaneous
pulmonary valve implantation.
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not ﬁnd a signiﬁcant shortening of QRSd in the cohort of
patients with purely pulmonary insufﬁciency. The reason for
this discrepancy might reside in the fact that our sample size
is too small to discern such difference.
Consistent with Plymen et al, the QTc in our study
uniformly increased immediately post-PPVI but shortened
beyond baseline at follow-up, regardless of type of RVOT
dysfunction. QTc is a parameter of repolarization and a
surrogate measurement of local action potential duration. It is
recognized that myocardial stretch, via contraction-excitation
feedback, increases monophasic action potential duration and
causes afterdepolarizations, which in turn can cause triggered
activity and generate the appropriate conditions for reentrant
arrhythmias.17 Contraction-excitation feedback has been
demonstrated in both increased pressure and volume load
conditions.18-20 For example, in the lamb, chronic PI led to
inhomogeneity of right ventricular activation, decreased
conduction velocity, and increased intracellular resistivity.
These changes might contribute to the observed increased
susceptibility to stretch-induced arrhythmias of the right
ventricle.19,20 Furthermore, when compared with the hyper-
trophied human myocardium, the dilated myocardium had
longer steady-state action potential duration.21 Consistent
with this observation, our study showed that patients with PI
had longer QTc than PS patients. Contraction-excitation
feedback and alterations in the local ventricular repolarization
also explain the signiﬁcant lengthening of QTc post-PPVI as
previously demonstrated in the context of pulmonary valve
valvuloplasty in PS patients.18 According to contraction-
excitation theory, repolarization duration is inversely propor-
tional to the mechanical stress on the myocardium. Therefore,
repolarization duration should be the longest after successful
reduction in afterload seen with repetitive balloon occlusions
of the RVOT during placement of stents and the pulmonary
valve in PPVI. Consistent with this observation, our study
showed that patients with PS had signiﬁcantly longer QTc
than PI patients immediately post-PPVI. It is important,
therefore, to recognize that abnormalities in both depolariza-
tion and repolarization contribute to the increased risks of
developing arrhythmia in patients with RVOT dysfunction.21
The ﬁnding that QRSd and QTc stabilized and improved post-
PPVI suggests that favorable changes in hemodynamics would
translate into more stable myocardial depolarization and
repolarization and reduce the risk of arrhythmias. Longer-term
follow-up would be needed to monitor QRSd and QTc
changes.
Other ST/T changes (such as nonspeciﬁc ST/T changes,
T-wave inversion, and ST depression) were also observed
immediately post-PPVI. These changes most likely reﬂect
transient ischemic injury that follows repeated total balloon
occlusions of the RVOT during RVOT angioplasty, transient
absent cardiac output during the check for coronary
artery compression, and rapid ventricular pacing during
3-dimensional rotational angiography in certain cases, or
perhaps coronary artery spasm caused by selective coronary
angiographies. These changes could also reﬂect the acute
changes in hemodynamics with the newly placed valve,
anesthesia effect, or possibly mechanical trauma of catheter
manipulation during the procedure. Interestingly, the majority
of these ST/T changes disappeared over time.
Despite favorable changes in measureable surface ECG
parameters, the long-term effects of RV remodeling on the
arrhythmias burden are unknown. Our mean follow-up period
is 31 months, which exceeds that of Plymen et al10 and
Piotrowicz et al11 and is on a par with previous surgical
pulmonary valve replacement series.16,22-26 Previously, Gen-
gsakul et al25 and Harrild et al26 studied matched pairs of
patients with repaired ToF with and without surgical pul-
monary valve replacement and showed no signiﬁcant change
in QRSd and impact on arrhythmia burden. Speciﬁcally,
Harrild et al26 reported no survival beneﬁt in death or
sustained ventricular tachycardia at a mean of 3 years of
follow-up. However, the myocardial incision incurred with the
surgical pulmonary valve replacement may represent another
confounding factor in their analysis. Therrien et al16 studied a
cohort of 70 patients who underwent pulmonary valve
replacement late after ToF repair with some patients with
preexisting arrhythmias undergoing intraoperative EP map-
ping and cryoablation. They found that the QRSd stabilized at
a mean of 4.7 years of follow-up and that there was a
Figure 6. Documented nonsustained ventricular tachycardia
(NSVT). Prior to procedure, NSVT was documented in 9 patients.
Seven patients had new-onset NSVT immediately postprocedure. At
follow-up, 4 of 9 patients who previously had NSVT preprocedure
continued to have NSVT, 1 of 9 patients no longer had NSVT but
had PVCs, and 4 of 9 patients no longer had NSVT. Among the
patients with new-onset NSVT postprocedure, 6 of 7 no longer had
nonsustained VT, while 1 patient had PVCs. NSVT indicates
nonsustained ventricular tachycardia; PVCs, premature ventricular
contractions.
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signiﬁcant decrease in the prevalence of monomorphic VT.
The prevalence of AF/AFL also decreased, albeit nonsignif-
icantly. Overall, our study reported a substantial decrease in
the prevalence of NSVT and PVCs post-PPVI. There was a
signiﬁcant incidence of new PVCs and NSVT immediately
post-PPVI. Importantly, most of these new arrhythmias
resolved after 6 months postprocedure. Some of the patients
required short-term antiarrhythmic therapy with a b-blocker
or amiodarone that was discontinued at their 6-month follow-
up. We attribute these changes to the irritability caused by
stents placed in the RVOT prior to the Melody valve
placement and possibly due to contraction-excitation feed-
back caused by myocardial stretch associated with the
repetitive balloon occlusion of the RVOT during placement of
stents and the pulmonary valve in PPVI. Moreover, previous
studies have shown that ventricular ectopy may be caused by
afterdepolarizations associated with increase in mechanical
stress.28,29 These arrhythmias would resolve once the stents
completely endothelialized and hemodynamics reached a
better steady state. Unfortunately, many of the patients in
our cohort received prestenting of the RVOT, precluding any
analysis of the effect of prestenting on arrhythmia burden.
Finally, PVCs and NSVT may be related to the underlying
anatomical heart defect, focal scarring, ﬁbrosis, or surgical
suture lines rather than to right ventricular outﬂow tract
dysfunction.
Figure 8. Atrial ﬁbrillation/atrial ﬂutter (AF/AFL). Ten patients
had documented AF/AFL pre-PPVI. One patient had new-onset AF/
AFL immediately postprocedure. At follow-up, 5 patients continued
to have AF/AFL (4 preprocedure and 1 new onset), while 6 patients
no longer had AF/AFL. AF/AFL indicates atrial ﬁbrillation/atrial
ﬂutter; PPVI, percutaneous pulmonary valve implantation.
Figure 7. Isolated premature ventricular contractions (PVCs). Six patients had documented frequent
isolated PVCs pre-PPVI. Immediately postprocedure, there was resolution of PVCs in 4 (64%) patients, while
1 (17%) patient continued to have persistent PVCs, and 1 (17%) patient had nonsustained ventricular
tachycardia (NSVT). Additionally, 8 patients had new-onset PVCs immediately postprocedure. Seven out of
8 patients with new-onset PVCs and both of the persistent PVCs postprocedure no longer had any
arrhythmia at follow-up. One patient with new-onset PVCs and the patient with persistent PVCs
immediately postprocedure continued to have PVCs at follow-up. The patient with persistent PVCs
throughout had an out-of-hospital sudden cardiac arrest. NSVT indicates nonsustained ventricular
tachycardia; PPVI, percutaneous pulmonary valve implantation; PVCs, premature ventricular contractions.
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This is a single-center retrospective study, with patient
attrition over time, which limited the power of our analysis.
Additionally, our cohort was heterogeneous in their anatom-
ical lesions, hemodynamics, and clinical status prior to the
procedure. Therefore, we predict that there is variability in
the beneﬁcial effects of improved hemodynamics on the
electrophysiology substrate and measurable ECG parame-
ters. An improved sample size would allow us to perform
more detailed subgroup analyses to better tease out the
different effects of PPVI. Despite most patients with
previously or newly diagnosed arrhythmias undergoing
follow-up Holter monitor evaluation at 6-month follow-up,
there was no uniform protocol for monitoring of PVCs and
NSVT over the follow-up period, which may lead to an
overestimation in the prevalence reduction of these
arrhythmias. Although our mean follow-up period is reason-
able at 31 months, long-term follow-up is still needed to
both assess the measurable ECG parameters and provide
better correlation with the arrhythmia burden. Last, a
potential limitation is that changes to the QTc may be
secondary to anesthesia, other medications, or electrolyte
anomalies. Patients in this study had ECGs obtained the
morning following PPVI placement, and changes to the QTc
were based on preprocedural ECG—as a result, each
patient was his or her own control.
Conclusions
Our study demonstrates that PPVI stabilizes the QRSd and
shortens the QTc in congenital heart disease patients with
RVOT dysfunction. Furthermore, there is a substantial
decrease in the prevalence of NSVT and PVCs post-PPVI.
Finally, acute changes to the electrophysiologic substrate and
arrhythmia burden immediately post-PPVI improve over time
at midterm follow-up. These ﬁndings suggest that PPVI is a
beneﬁcial procedure from an electrophysiologic standpoint.
Further prospective and long-term studies would be needed to
further deﬁne and assess the causal effects of PPVI on
electrophysiologic changes in these patients.
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